Literature DB >> 20865304

Tikhonov adaptively regularized gamma variate fitting to assess plasma clearance of inert renal markers.

Carl A Wesolowski1, Richard C Puetter, Lin Ling, Paul S Babyn.   

Abstract

The Tk-GV model fits Gamma Variates (GV) to data by Tikhonov regularization (Tk) with shrinkage constant, λ, chosen to minimize the relative error in plasma clearance, CL (ml/min). Using (169)Yb-DTPA and (99m)Tc-DTPA (n = 46, 8-9 samples, 5-240 min) bolus-dilution curves, results were obtained for fit methods: (1) Ordinary Least Squares (OLS) one and two exponential term (E₁ and E₂), (2) OLS-GV and (3) Tk-GV. Four tests examined the fit results for: (1) physicality of ranges of model parameters, (2) effects on parameter values when different data subsets are fit, (3) characterization of residuals, and (4) extrapolative error and agreement with published correction factors. Test 1 showed physical Tk-GV results, where OLS-GV fits sometimes-produced nonphysical CL. Test 2 showed the Tk-GV model produced good results with 4 or more samples drawn between 10 and 240 min. Test 3 showed that E₁ and E₂ failed goodness-of-fit testing whereas GV fits for t > 20 min were acceptably good. Test 4 showed CL(Tk-GV) clearance values agreed with published CL corrections with the general result that CL(E1) > CL(E2) > CL(Tk-GV) and finally that CL(Tk-GV) were considerably more robust, precise and accurate than CL(E2), and should replace the use of CL(E2) for these renal markers.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20865304      PMCID: PMC2953622          DOI: 10.1007/s10928-010-9167-z

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  43 in total

1.  INDICATOR TRANSIT TIME CONSIDERED AS A GAMMA VARIATE.

Authors:  H K THOMPSON; C F STARMER; R E WHALEN; H D MCINTOSH
Journal:  Circ Res       Date:  1964-06       Impact factor: 17.367

2.  Volumes of distribution and clearances of intravenously injected creatinine in the dog.

Authors:  L A SAPIRSTEIN; D G VIDT; M J MANDEL; G HANUSEK
Journal:  Am J Physiol       Date:  1955-05

3.  Conventional measurements of GFR using 51Cr-EDTA overestimate true renal clearance by 10 percent.

Authors:  Amelia E B Moore; So-Jin Park-Holohan; Glen M Blake; Ignac Fogelman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-10-26       Impact factor: 9.236

4.  Indicator-dilution dispersion models and cardiac output computing methods.

Authors:  R K Millard
Journal:  Am J Physiol       Date:  1997-04

5.  Variability of glomerular filtration rate estimation using single injection methods in Type 1 diabetic patients.

Authors:  A Siebenhofer; A Meinitzer; J Brandmair; J Plank; T R Pieber
Journal:  Diabet Med       Date:  2001-06       Impact factor: 4.359

6.  Measurement of glomerular filtration rate: single injection plasma clearance method without urine collection.

Authors:  C D Russell; P G Bischoff; F N Kontzen; K L Rowell; M V Yester; L K Lloyd; W N Tauxe; E V Dubovsky
Journal:  J Nucl Med       Date:  1985-11       Impact factor: 10.057

7.  Negative power functions of time in pharmacokinetics and their implications.

Authors:  M E Wise
Journal:  J Pharmacokinet Biopharm       Date:  1985-06

8.  Comparison of inulin, iothalamate, and 99mTc-DTPA for measurement of glomerular filtration rate.

Authors:  G L Barbour; C K Crumb; C M Boyd; R D Reeves; S P Rastogi; R M Patterson
Journal:  J Nucl Med       Date:  1976-04       Impact factor: 10.057

9.  Simultaneous measurement of renal clearance and plasma clearance of 99mTc-labelled diethylenetriaminepenta-acetate, 51Cr-labelled ethylenediaminetetra-acetate and inulin in man.

Authors:  M Rehling; M L Møller; B Thamdrup; J O Lund; J Trap-Jensen
Journal:  Clin Sci (Lond)       Date:  1984-05       Impact factor: 6.124

10.  Optimum sample times for single-injection, multisample renal clearance methods.

Authors:  C D Russell
Journal:  J Nucl Med       Date:  1993-10       Impact factor: 10.057

View more
  7 in total

1.  Validation of Tikhonov adaptively regularized gamma variate fitting with 24-h plasma clearance in cirrhotic patients with ascites.

Authors:  Carl Adam Wesolowski; Lin Ling; Elias Xirouchakis; Maria T Burniston; Richard C Puetter; Paul S Babyn; Ioannis G Giamalis; Andrew K Burroughs
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-09-01       Impact factor: 9.236

2.  The early plasma concentration of 51Cr-EDTA in patients with cirrhosis and ascites: a comparison of three models.

Authors:  Surajith N Wanasundara; Michal J Wesolowski; Richard C Puetter; Maria T Burniston; Elias Xirouchakis; Ioannis G Giamalis; Paul S Babyn; Carl A Wesolowski
Journal:  Nucl Med Commun       Date:  2015-04       Impact factor: 1.690

3.  Accurate and precise plasma clearance measurement using four 99mTc-DTPA plasma samples over 4 h.

Authors:  Surajith N Wanasundara; Michal J Wesolowski; Mark C Barnfield; Michael L Waller; Anthony W Murray; Maria T Burniston; Paul S Babyn; Carl A Wesolowski
Journal:  Nucl Med Commun       Date:  2016-01       Impact factor: 1.690

4.  Time Varying Apparent Volume of Distribution and Drug Half-Lives Following Intravenous Bolus Injections.

Authors:  Carl A Wesolowski; Michal J Wesolowski; Paul S Babyn; Surajith N Wanasundara
Journal:  PLoS One       Date:  2016-07-12       Impact factor: 3.240

5.  A gamma-distribution convolution model of 99mTc-MIBI thyroid time-activity curves.

Authors:  Carl A Wesolowski; Surajith N Wanasundara; Michal J Wesolowski; Belkis Erbas; Paul S Babyn
Journal:  EJNMMI Phys       Date:  2016-12-16

6.  A series acceleration algorithm for the gamma-Pareto (type I) convolution and related functions of interest for pharmacokinetics.

Authors:  Carl A Wesolowski; Jane Alcorn; Geoffrey T Tucker
Journal:  J Pharmacokinet Pharmacodyn       Date:  2021-10-24       Impact factor: 2.745

7.  Comparison of the gamma-Pareto convolution with conventional methods of characterising metformin pharmacokinetics in dogs.

Authors:  Carl A Wesolowski; Surajith N Wanasundara; Paul S Babyn; Jane Alcorn
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-12-21       Impact factor: 2.745

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.